Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	134.90B
Revenue (ttm)	22.74B
Net Income (ttm)	4.42B
Shares Out	122.63M
EPS (ttm)	35.93
PE Ratio	30.61
Forward PE	24.06
Dividend	22.50 (2.05%)
Ex-Dividend Date	n/a

Volume	110,635
Average Volume	106,631
Open	1,129.70
Previous Close	1,115.60
Day's Range	1,089.90 - 1,135.00
52-Week Range	850.00 - 1,251.00
Beta	0.19
RSI	57.61
Earnings Date	Apr 24, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2023, Alivus Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.